Abstract: The present invention relates to a pharmaceutical composition for treating autism spectrum disorders, which includes clioquinol or pharmaceutically acceptable salt thereof. In addition, the present invention relates to a food composition for treating autism spectrum disorders, which includes clioquinol or pharmaceutically acceptable salt thereof.

Abstract: The present disclosure relates to a diagnostic kit capable of accurately diagnosing diseases or disorders related with abnormal aggregation or misfolding of proteins, including disorders or diseases caused by aggregation of ?-amyloid such as Alzheimer's disease as well as disorders or diseases caused by aggregation of other proteins, based on concentration analysis of the aggregated proteins before and after dissociation.

Abstract: The present application describes an isolated nucleic acid molecule encoding a polypeptide capable of synchronously binding VEGF polypeptide and placenta growth factor (PIGF) polypeptide comprising a nucleotide sequence encoding a VEGFR1 component.

Abstract: The present application discloses a method of promoting differentiation and expansion of endothelial cells (EC) and cardiomyocytes from a pluripotent cell, which includes contacting the pluripotent cell with a Rho-associated protein kinase (ROCK) suppressor.

Abstract: The present invention relates to an animal model for evaluating hemostatic performance, and the use thereof, and more particularly, to an animal model for evaluating the performance of a hemostatic agent, which has hemorrhage induced in the common carotid artery (CCA) or superior sagittal sinus (SSS) of the animal, a method of screening a hemostatic agent using the animal model, and a method of evaluating the effect of a hemostatic agent using the animal model. The animal model according to the present invention makes it possible to observe the hemostatic effect of a hemostatic agent in a rapid and accurate manner without causing side effects. Thus, the animal model is useful for screening a hemostatic agent and evaluating the effect of a hemostatic agent.

Abstract: The present application describes an isolated nucleic acid molecule encoding a polypeptide capable of synchronously binding VEGF polypeptide and TNF polypeptide comprising: (a) a nucleotide sequence encoding a TNFR2 component and VEGFR1 component operatively linked to (b) a nucleotide sequence encoding a multimerizing component, wherein the TNFR2 component consists essentially of a nucleotide sequence encoding the amino acid sequences of cystein rich domain 1, cystein rich domain 2, cystein rich domain 3, and cystein rich domain 4 of the extracellular domain of TNFR2, and wherein the VEGFR1 component consists essentially of a nucleotide sequence encoding the amino acid sequences of Ig-like domain 2 of the extracellular domain of VEGFR1.

Abstract: A method of preventing or treating cancer using an anti-Ang2 antibody or an antigen-binding fragment thereof that specifically binds to an angiogenesis-inducing factor Angiopoietin-2 (Ang2) and complexes to a Tie2 receptor while bound with Ang2.

Abstract: The present application describes an isolated nucleic acid molecule encoding a polypeptide capable of synchronously binding VEGF polypeptide and TNF polypeptide comprising: (a) a nucleotide sequence encoding a TNFR2 component and VEGFR1 component operatively linked to (b) a nucleotide sequence encoding a multimerizing component, wherein the TNFR2 component consists essentially of a nucleotide sequence encoding the amino acid sequences of cystein rich domain 1, cystein rich domain 2, cystein rich domain 3, and cystein rich domain 4 of the extracellular domain of TNFR2, and wherein the VEGFR1 component consists essentially of a nucleotide sequence encoding the amino acid sequences of Ig-like domain 2 of the extracellular domain of VEGFR1.

Abstract: The present application describes a method of inhibiting tumor growth including contacting the tumor with a compound that inhibits activity of RhoJ protein.

Abstract: Provided is a composition for preventing or treating erectile dysfunction including angiopoietin-4 protein as an active ingredient. Angiopoietin-4 protein increases an endothelial cell-specific protein level to induce regeneration of penile vascular endothelial cells, thereby increasing intracavernous pressure. Thus, angiopoietin-4 protein may be efficiently applied to prevention or treatment of erectile dysfunction.

Abstract: A method for fabricating a semiconductor device includes forming a recess pattern by selectively etching a substrate; forming a gate dielectric layer filling the recess pattern on the substrate; forming a groove by selectively etching the gate dielectric layer; forming a polysilicon electrode filling the groove; forming an electrode metal layer on the polysilicon electrode and the gate dielectric layer; and forming a gate pattern by etching the electrode metal layer and the gate dielectric layer. The recess pattern is formed along an edge portion of the gate pattern as a quadrilateral periphery.

Abstract: The present application discloses a method of treating a disease that is treatable by therapeutic angiogenesis comprising administering to a needy subject an effective amount of a chimeric coiled coil molecule comprising a coiled-coil domain linked to a receptor binding domain of a ligand.

Abstract: The present application discloses a method of treating a disease that is treatable by therapeutic angiogenesis comprising administering to a needy subject an effective amount of a chimeric coiled coil molecule comprising a coiled-coil domain linked to a receptor binding domain of a ligand.

Abstract: The present application discloses a method of treating a disease that is treatable by therapeutic angiogenesis comprising administering to a needy subject an effective amount of a chimeric coiled coil molecule comprising a coiled-coil domain linked to a receptor binding domain of a ligand.

Abstract: A method for fabricating a semiconductor device includes forming a recess pattern by selectively etching a substrate; forming a gate dielectric layer filling the recess pattern on the substrate; forming a groove by selectively etching the gate dielectric layer; forming a polysilicon electrode filling the groove; forming an electrode metal layer on the polysilicon electrode and the gate dielectric layer; and forming a gate pattern by etching the electrode metal layer and the gate dielectric layer. The recess pattern is formed along an edge portion of the gate pattern as a quadrilateral periphery.

Abstract: The present application discloses a method of treating a disease that is treatable by therapeutic angiogenesis comprising administering to a needy subject an effective amount of a chimeric coiled coil molecule comprising a coiled-coil domain linked to a receptor binding domain of a ligand.